LOGIN  |  REGISTER
Amneal Pharmaceuticals
Recursion

BrightSpring Health Services to Participate in Two Upcoming Investor Conferences

November 21, 2024 | Last Trade: US$17.27 0.23 1.35

LOUISVILLE, Ky., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that Company management will participate at two upcoming virtual investor conferences.

  • BTIG Virtual Digital Health Forum
    Panel on Monday, November 25th at 9:00AM ET
  • Bank of America Virtual Home Care Conference 2024
    Fireside Chat on Tuesday, December 10th at 2:10PM ET

A live and archived webcast of the Bank of America Home Care Conference Fireside Chat will be available on the “Event & Presentations” section of the BrightSpring investor relations website at https://ir.brightspringhealth.com/.

About BrightSpring Health Services

BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.

Contact

Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:
Leigh White
This email address is being protected from spambots. You need JavaScript enabled to view it. 
502.630.7412

Chimerix

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB